# Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

> **NCT00216008** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 42 (—)

## Conditions studied

- Esophageal Adenocarcinomas
- Adenocarcinomas of the Gastroesophageal Junction

## Interventions

- **DRUG:** docetaxel
- **DRUG:** cisplatin
- **PROCEDURE:** radiation
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00216008
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 42 (—)
- **Why stopped:** IRB Closure
- **Last updated:** 2013-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216008, "Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00216008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*